Figure 8.

Systemic delivery of DAPK1 enhances bacterial translocation in vivo. Male C57Bl/6 mice were treated with 2.5% (w/v) DSS (∼40 kDa) in their drinking water for 5 days (A–F). Additional mice received the DAPK1 inhibitor DAPK6 (20 μg/kg, i.p. daily). Mice were euthanized, and disease activity was assessed in the DSS-treated mice, and bacterial translocation into the colonic mucosa, MLN, and spleen was determined in all mice. G–I, male C57Bl/6 mice were intra-rectally administered DNP (3 mm) for 24 h. Additional mice received DAPK6 (20 μg/kg, i.p. daily) ± TM (20 μg/kg, i.p. daily). Mice were euthanized, and bacterial translocation into the colonic mucosa, MLN, and spleen was determined in all mice (mean ± S.D.; * and #, p < 0.05 compared with control and DSS or DNP, respectively).